Exploring Hepatotoxicity and Treatment Outcomes of Targeting KRAS G12C Mutations in mNSCLC : Episode 7

Opinion

Video

December 21, 2023

CodeBreaK 200: Sotorasib in Second Line KRAS G12C-Mutated NSCLC

Author(s):

Joshua K. Sabari, MD,Edward B. Garon, MD, MS

Dr. Sabari and Dr. Garon discuss second line sotorasib and the results of the CodeBreaK 200 study, highlighting the recent FDA oncologic drugs advisory committee (ODAC) and their assessment of the study results.

EP: 1.The State of Targeted Therapies in NSCLC

EP: 2.Frontline Treatments for KRAS G12C-Mutation mNSCLC

EP: 3.Clinical Perspectives of KRAS G12C Inhibitors in NSCLC Mutations

EP: 4.The Role of KRAS G12C Inhibitors in Frontline Metastatic NSCLC

EP: 5.Clinical Data Review of Hepatotoxicity in Frontline KRAS G12C Inhibition

EP: 6.Disease Progression Beyond Frontline KRAS G12C Inhibitors

Now Viewing

EP: 7.CodeBreaK 200: Sotorasib in Second Line KRAS G12C-Mutated NSCLC

EP: 8.KRAS Inhibitors: Hepatotoxicity and Adverse Events in 2L Metastatic NSCLC

EP: 9.Practical Management of Hepatotoxicity in KRAS G12C Inhibitors

EP: 10.Future Perspectives in KRAS G12C-Mutated NSCLC

Related Content

OncLive's OncFive: The Top 5 Oncology Articles of the Week

December 21st 2024

The OncFive: Top Oncology Articles for the Week of 12/15

December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

December 20th 2024

China’s NMPA Approves Taletrectinib in Previously Treated ROS1+ Advanced NSCLC

October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

December 18th 2024

FDA Approves Ensartinib for Locally Advanced or Metastatic ALK+ NSCLC

December 17th 2024

FDA Grants Breakthrough Therapy Designation to Sacituzumab Govitecan for Second-Line ES-SCLC